Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and
CHICAGO, April 5, 2013
CHICAGO, April 5, 2013 /PRNewswire/ --Today, Zacks Equity Research discusses
the U.S. Pharma & Biotech, including Eli Lilly (NYSE:LLY), Novo Nordisk
(NYSE:NVO), Biogen (Nasdaq:BIIB), Amgen (Nasdaq:AMGN) and Osiris Therapeutics
A synopsis of today's Industry Outlook is presented below. The full article
can be read at
We continue to have a Neutral outlook on large-cap pharma stocks. While the
companies will continue to face challenges like EU austerity measures and
genericization, the pharma industry should be out of the worst of the
genericization phase from 2013.
Several companies which had faced generic headwinds in the last couple of
years should see their results recover from 2013. Cost-cutting, downsizing,
streamlining of the pipeline, growth in emerging markets and product approvals
should support growth.
Zacks Rank #2 (Buy) stocks in the pharma sector include Eli Lilly (NYSE:LLY)
and Novo Nordisk (NYSE:NVO), among others. Despite the presence of generic
competition for key products, share buybacks and cost control should help Eli
Lilly achieve its 2013 guidance.
In the biotech space, we are positive on Biogen (Nasdaq:BIIB). We are
optimistic on Tecfidera, the company's oral multiple sclerosis drug which
gained approval last week. Key products, Avonex and Tysabri, should continue
contributing significantly to sales. The company is also progressing with its
We are also positive on Amgen (Nasdaq:AMGN). Amgen's 2013 guidance was above
expectations. The company also provided an update on its long-term strategy.
Amgen should be able to deliver on its long-term strategy based on expansion
in key markets, launch of new manufacturing technologies, and pipeline
development. Enbrel should continue performing well. Amgen's late-stage
pipeline is also moving along.
Both Biogen and Amgen are Zacks Rank #2 stocks. Gilead, another Zacks Rank #2
stock, continues to do well in the HIV segment.
Osiris Therapeutics (Nasdaq:OSIR), a stem cell company, currently carries a
Zacks Rank #1 (Strong Buy). Prochymal's approval in Canada and New Zealand
were major milestones for the company. Meanwhile, the Biosurgery segment is
also gaining traction. A partnership deal for Prochymal would be a major boost
for the stock.
Among generic companies, Mylan carries a Zacks Rank #2. We are encouraged by
Mylan's geographic reach and product depth and robust generic product
Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from the Pros. In
short, it's your steady flow of Profitable ideas GUARANTEED to be worth your
time! Register for your free subscription to Profit from the Pros at
Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/ZacksInvestmentResearch
Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
Zacks Investment Research
800-767-3771 ext. 9339
SOURCE Zacks Investment Research, Inc.
Press spacebar to pause and continue. Press esc to stop.